Targeting of temozolomide using magnetic nanobeads: an in vitro study
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Pharmaceutical Sciences |
Texto Completo: | https://www.revistas.usp.br/bjps/article/view/181846 |
Resumo: | Temozolomide, a chemotherapeutic drug that is often administered for the treatment of brain cancer has severe side effects and a poor aqueous solubility. In order to decrease the detrimental effect of the drug over healthy cells, a novel drug delivery vehicle was developed where the therapeutic drug was encapsulated within the hydrophobic cavities of b-CD modified magnetite nanoparticles, which are embedded in chitosan nanobeads prepared by salt addition. In-vitro studies have shown that the magnetic properties of the novel delivery vehicle are adequate for targeted drug delivery applications under an external magnetic field. Additionally, an increase in the amount of chitosan was shown to exhibit a strong shielding effect over the magnetic properties of the delivery vehicle, which lead to deterioration of the amount of captured drug at the targeted area, suggesting a delicate balance between the amounts of constituents composing the drug delivery vehicle. |
id |
USP-31_acf3a6b130f815ab7dacfa4303d85edd |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/181846 |
network_acronym_str |
USP-31 |
network_name_str |
Brazilian Journal of Pharmaceutical Sciences |
repository_id_str |
|
spelling |
Targeting of temozolomide using magnetic nanobeads: an in vitro studyTemozolomideMagnetiteCyclodextrinChitosanTargetingAnticancerTemozolomide, a chemotherapeutic drug that is often administered for the treatment of brain cancer has severe side effects and a poor aqueous solubility. In order to decrease the detrimental effect of the drug over healthy cells, a novel drug delivery vehicle was developed where the therapeutic drug was encapsulated within the hydrophobic cavities of b-CD modified magnetite nanoparticles, which are embedded in chitosan nanobeads prepared by salt addition. In-vitro studies have shown that the magnetic properties of the novel delivery vehicle are adequate for targeted drug delivery applications under an external magnetic field. Additionally, an increase in the amount of chitosan was shown to exhibit a strong shielding effect over the magnetic properties of the delivery vehicle, which lead to deterioration of the amount of captured drug at the targeted area, suggesting a delicate balance between the amounts of constituents composing the drug delivery vehicle.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2020-12-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/18184610.1590/s2175-97902019000418579Brazilian Journal of Pharmaceutical Sciences; Vol. 56 (2020); e18579Brazilian Journal of Pharmaceutical Sciences; v. 56 (2020); e18579Brazilian Journal of Pharmaceutical Sciences; Vol. 56 (2020); e185792175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/181846/168742Copyright (c) 2020 Brazilian Journal of Pharmaceutical Scienceshttp://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessGürten, Berna Yenigül, Elçin Sezer, Ali Demir Altan, Cem Malta, Seyda 2021-06-12T19:46:54Zoai:revistas.usp.br:article/181846Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2021-06-12T19:46:54Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Targeting of temozolomide using magnetic nanobeads: an in vitro study |
title |
Targeting of temozolomide using magnetic nanobeads: an in vitro study |
spellingShingle |
Targeting of temozolomide using magnetic nanobeads: an in vitro study Gürten, Berna Temozolomide Magnetite Cyclodextrin Chitosan Targeting Anticancer |
title_short |
Targeting of temozolomide using magnetic nanobeads: an in vitro study |
title_full |
Targeting of temozolomide using magnetic nanobeads: an in vitro study |
title_fullStr |
Targeting of temozolomide using magnetic nanobeads: an in vitro study |
title_full_unstemmed |
Targeting of temozolomide using magnetic nanobeads: an in vitro study |
title_sort |
Targeting of temozolomide using magnetic nanobeads: an in vitro study |
author |
Gürten, Berna |
author_facet |
Gürten, Berna Yenigül, Elçin Sezer, Ali Demir Altan, Cem Malta, Seyda |
author_role |
author |
author2 |
Yenigül, Elçin Sezer, Ali Demir Altan, Cem Malta, Seyda |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Gürten, Berna Yenigül, Elçin Sezer, Ali Demir Altan, Cem Malta, Seyda |
dc.subject.por.fl_str_mv |
Temozolomide Magnetite Cyclodextrin Chitosan Targeting Anticancer |
topic |
Temozolomide Magnetite Cyclodextrin Chitosan Targeting Anticancer |
description |
Temozolomide, a chemotherapeutic drug that is often administered for the treatment of brain cancer has severe side effects and a poor aqueous solubility. In order to decrease the detrimental effect of the drug over healthy cells, a novel drug delivery vehicle was developed where the therapeutic drug was encapsulated within the hydrophobic cavities of b-CD modified magnetite nanoparticles, which are embedded in chitosan nanobeads prepared by salt addition. In-vitro studies have shown that the magnetic properties of the novel delivery vehicle are adequate for targeted drug delivery applications under an external magnetic field. Additionally, an increase in the amount of chitosan was shown to exhibit a strong shielding effect over the magnetic properties of the delivery vehicle, which lead to deterioration of the amount of captured drug at the targeted area, suggesting a delicate balance between the amounts of constituents composing the drug delivery vehicle. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-12-09 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/181846 10.1590/s2175-97902019000418579 |
url |
https://www.revistas.usp.br/bjps/article/view/181846 |
identifier_str_mv |
10.1590/s2175-97902019000418579 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/181846/168742 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2020 Brazilian Journal of Pharmaceutical Sciences http://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2020 Brazilian Journal of Pharmaceutical Sciences http://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
dc.source.none.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences; Vol. 56 (2020); e18579 Brazilian Journal of Pharmaceutical Sciences; v. 56 (2020); e18579 Brazilian Journal of Pharmaceutical Sciences; Vol. 56 (2020); e18579 2175-9790 1984-8250 reponame:Brazilian Journal of Pharmaceutical Sciences instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Brazilian Journal of Pharmaceutical Sciences |
collection |
Brazilian Journal of Pharmaceutical Sciences |
repository.name.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
bjps@usp.br||elizabeth.igne@gmail.com |
_version_ |
1800222915155722240 |